Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT01259726 - Clostridioides difficile M3 (NTCD-M3 spores) & Clostridioides difficile infection (CDI) (recurrent)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Study overview:

NCT01259726 - Clostridioides difficile M3 (NTCD-M3 spores) & Clostridioides difficile infection (CDI) (recurrent) is a randomized clinical phase II dose-ranging trial studying NTCD-M3 spores in 173 enrolled patients aged 18 years or older with Clostridioides difficile infection (CDI) (recurrent) (first episode or first recurrence) (1)

Primary outcome measures:

Safety and tolerability of Clostridioides difficile M3 (NTCD-M3 spores) within 7 days of treatment (1)

Results:

In the study, treatment-emergent adverse events were observed in 78% of patients who received Clostr…

References (Sources)

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial
Gerding et al. 2015 JAMA 313: 1719-27

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!